(RTTNews) - Johnson & Johnson (JNJ), Thursday announced results from additional analyses of the Phase 2 DAHLIAS study, evaluating the effects of Nipocalimab in participants with primary Sjogren's ...

Nipocalimab was well-tolerated over the six-month study period, with no major safety signals observed. The most common adverse events (AEs) were infections and infestations: 60.4% (n=32) in the ...

On Tuesday, Johnson & Johnson (JNJ) stock saw a decline, ending the day at $152.64 which represents a decrease of $-2.40 or -1.55% from the prior close of $155.04. The stock opened at $154.53 and ...

Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...

HRSA’s threats of penalties led J&J to halt the plan, prompting a legal battle to protect its proposed changes. Johnson & ...

Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us ...

In my view, such adjustments are totally acceptable, and I shared my reasons - although obviously not directly comparable - ...

On Friday, Johnson & Johnson (JNJ) stock saw a decline, ending the day at $155.47 which represents a decrease of $-1.26 or -0.80% from the prior close of $156.73. The stock opened at $157 and touched ...

Johnson & Johnson has a high three-year median payout ratio of 71% (or a retention ratio of 29%), meaning that the company is ...

Julian Harrison gave his rating based on several factors surrounding Protagonist Therapeutics’ promising drug candidate, JNJ-2113. The upcoming Phase 3 trial data for JNJ-2113 in psoriasis is pivotal, ...

GET MORE AI-GENERATED SIGNALS: November 09, 2024, 09:42 am ET, BY Chris- Contributor| Editor: Thomas H. Kee Jr. ( Follow on ...

The first time Johnson & Johnson faced a lawsuit due to its talc-based baby powder causing cancer was way back in 1999.